60 Degrees Pharmaceuticals, Inc. Forecasted to Post Q3 2024 Earnings of ($0.93) Per Share (NASDAQ:SXTP)

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) – Analysts at HC Wainwright increased their Q3 2024 earnings estimates for shares of 60 Degrees Pharmaceuticals in a research report issued on Thursday, August 15th. HC Wainwright analyst E. White now expects that the company will earn ($0.93) per share for the quarter, up from their previous estimate of ($1.44). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($6.72) per share. HC Wainwright also issued estimates for 60 Degrees Pharmaceuticals’ Q4 2024 earnings at ($0.97) EPS, FY2024 earnings at ($5.43) EPS, FY2025 earnings at ($0.68) EPS and FY2026 earnings at ($0.23) EPS.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($4.23) EPS for the quarter, missing analysts’ consensus estimates of ($2.79) by ($1.44). The firm had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.11 million.

60 Degrees Pharmaceuticals Trading Up 1.3 %

Shares of SXTP opened at $1.58 on Monday. The company has a market cap of $19.29 million and a price-to-earnings ratio of -1.52. The business’s fifty day simple moving average is $0.38 and its two-hundred day simple moving average is $0.31. 60 Degrees Pharmaceuticals has a 12 month low of $1.03 and a 12 month high of $19.80.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.